New start-up company, Gyros AB, completes move to Swedish center of biotechnology and begins expansion.


The new biotech company, Gyros AB, has moved to new office and laboratory facilities in Uppsala Science Park, Sweden and begun expansion of its R & D, marketing and sales organizations.

Gyros AB announced today the completion of its move to Uppsala Science Park, Sweden after its spin off from Amersham Pharmacia Biotech, a leading supplier to the life science market.

Gyros AB offers pharmaceutical, biotechnology and diagnostic companies access to a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into client-specific CDs. Thousands of analyses can be performed in parallel on each disposable microlaboratory. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures.

Our initial contacts with pharmaceutical and diagnostic clients have been extremely positive’ said Maris Hartmanis, President and CEO of Gyros AB ‘They have seen immediately the advantages offered by such a unique technology platform.’ The proprietary technology of Gyros AB has been under development at Amersham Pharmacia Biotech over the previous decade. During this period a significant patent portfolio, now owned by Gyros, has been established. ‘We are now in a process of rapid expansion’ said Per Sjöberg, Vice President Commercial Operations at Gyros AB, ‘Interest from clients throughout the world has convinced us that now is the time to present this novel technology to the market place.’

Gyros AB shareholders include the Swedish investors The National Pension Insurance Fund (Sixth Fund Board), Investor Growth Capital, Karolinska Investment Fund, the Swedish Union of Clerical and Technical Employees in Industry, HealthCap, the Danish investor BankInvest and Amersham Pharmacia Biotech.

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.